Salipro Biotech Gains European Patent for Novel Method of Membrane Protein Extraction and Library Generation

February 17, 2021
BioPharm International Editors

Salipro Biotech has been granted a European Patent for its novel method of direct extraction of membrane proteins and for the generation of libraries with Salipro particles.

Swedish biotech, Salipro Biotech, has been granted a European Patent for its novel method of direct extraction of membrane proteins (DirectMX) and for the generation of libraries with Salipro particles, the company announced in a Feb. 17, 2021 press release.

The “Saposin lipoprotein particles and libraries from crude membranes” patent covers the use of DirectMX from cells or crude membranes to enable drug development of challenging drug targets. Additionally, the generation of libraries with Salipro particles representing the membrane proteome, the particles themselves, and their uses is covered.

“Ever since its inception, DirectMX has had a profound impact on how we accelerate drug discovery with our pharma partners,” said Jens Frauenfeld, CEO, Salipro Biotech in the press release. “Our foundational [intellectual property] covering the Salipro platform technology has already resulted in various patents being granted to Salipro Biotech in the [United States], [European Union], China, and Japan, and this patent will provide additional broad protection for our proprietary platform technology for the stabilization of challenging drug targets.”

Maria Knudsen, business developer, Salipro Biotech, added in the press release, “DirectMX is rapidly becoming established as a key drug discovery platform and we are already partnering with major pharma companies on a range of targets. Further strengthening our patent portfolio will enable us to increase the value of such collaborations as well as moving towards building our own discovery pipeline.”

Source: Salipro Biotech